Inicio>>Isotope-Labeled Compounds>>3-epi-25-Hydroxy Vitamin D3-d6

3-epi-25-Hydroxy Vitamin D3-d6

Catalog No.GC70854

3-epi-25-Hydroxy Vitamin D3-d6 es el deuterio labeled3-epi-25-hidroxi vitamina D3.

Products are for research use only. Not for human use. We do not sell to patients.

3-epi-25-Hydroxy Vitamin D3-d6 Chemical Structure

Cas No.: 2483831-27-0

Tamaño Precio Disponibilidad Cantidad
250 µg
2.037,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
3-epi-25-Hydroxy Vitamin D3-d6is the deuterium labeled3-epi-25-Hydroxy Vitamin D3. 3-epi-25-Hydroxy Vitamin D3 is the vitamin D metabolite, while vitamin D metabolism highly dependent on macrophage polarization. The C3-epimerase pathway for vitamin D is active in macrophages.

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

References:
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
[2]. Nygaard RH, et al'. Metabolism of 25-Hydroxy-Vitamin D in Human Macrophages Is Highly Dependent on Macrophage Polarization. Int J Mol Sci. 2022 Sep 19;23(18):10943.

Reseñas

Review for 3-epi-25-Hydroxy Vitamin D3-d6

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 3-epi-25-Hydroxy Vitamin D3-d6

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.